Allergan Sales, LLC v. Sandoz, Inc., No. 17-1499 (Fed. Cir. Dec. 22, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Allergan Sales, LLC sued generic drug manufacturers under the Hatch -Waxman Act, alleging infringement of U.S. P atent Nos. 7,030,149, 7,320,976, and 8,748,425. The U.S. District Court for the Eastern District of Texas found the asserted claims not in valid but only claims of the ’425 patent infringed. We find no reversible error in the district court’s finding of no invalidity.